Initial evaluation in A549 (wild-type EGFR) and HCC827 (exon 19 deletion EGFR) tumors showed moderate tumor uptake in both models (about or under 1%ID/g from 0–120 min p.i.). The gene discussed is EGFR; the disease is neoplasm.